These studies provided evidence that SMAD2 downregulation in patients with MMD might promote angiogenesis, proliferation and phenotype switching of VSMCs, which are the important characteristics of MMD mentioned before (Ma et al., 2022; He et al., 2023c; He et al., 2023d). Here, SMAD2 is linked to multiminicore myopathy.